ASCO

ASCO highlights immuno-oncology challenges

ASCO highlights immuno-oncology challenges

By

The potential of immunotherapy is great, but the news from the 2014 medical meeting shows that great may not be gargantuan in terms of treatment reach.

Which companies stand out post-ASCO?

Which companies stand out post-ASCO?

ASCO not only offered a peek at developing treatments likely to be commercialized. Its impact also put some companies in the limelight from a business-development perspective.

Novartis readying 2014 filing for lung cancer drug

Novartis readying 2014 filing for lung cancer drug

By

Novartis is advancing its "breakthrough" lung cancer drug into Phase III based on promising Phase I data.

GSK gets 2 cancer pills approved, but a deeper question is left unanswered

GSK gets 2 cancer pills approved, but a deeper question is left unanswered

By

GSK's newest cancer approvals highlight a problem that stalks progress with personalized medicines.

Roche's Rituxan successor receives high marks

By

Genentech's blockbuster follow-up shows promise in preliminary Phase III data

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.